Keywords: gvax, failure, offers, lessons, immunotherapy, trials, cell

GVAX failure offers "lessons" for immunotherapy trials

Article | 09 March 2009

Print This

Cell Genesys has released new data from VITAL-1, an abandoned Phase III study of its GVAX prostate cancer vaccine which ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in